Role of Nutrition and Hormones in Boys With Disordered Growth
NCT00102258 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2017-07-02
Summary
This study will determine whether adding more calories to the diet helps boys with growth problems grow better while being treated with Nutropin, a growth hormone that is used to help children grow taller. The Food and Drug Administration has approved Nutropin for use in children who are very short. This study will examine whether giving nutritional supplements in addition to Nutropin can help children grow better than with Nutropin alone.
Boys between 7 and 10 years of age who are very short and below average in weight, but are otherwise healthy may be eligible for this study. Candidates must qualify for Nutropin treatments to boost their growth. Boys will be recruited for the study from the Nemours Children's Clinic in Jacksonville, FL, and from the National Institutes of Health in Bethesda, MD.
Participants are randomly assigned to one of two treatment groups. One group is observed for 6 months and then receives a Nutropin injection every day for 12 months. The second group drinks 8 ounces of a high-calorie beverage called Pediasure every day for 6 months and then receives Nutropin plus Pediasure every day for 12 months. In addition to treatment, participants undergo the following tests and procedures at the schedule indicated: Baseline, 3, 6, 9, 12, 15 and 18 months
* Clinical examination
* Height measurement
* Body composition assessment: Skin-fold thickness calipers are used in four places on the body to estimate body fat
* Bioelectric impedance: A small amount of electrical current is used to calculate the percentage of body fat.
Baseline, 6, 12, and 18 months
* Blood tests
* Bone age x-ray: x-ray of the left hand to measure growth potential
* DEXA (dual energy x-ray absorptiometry) scan: x-ray scan to measure body fat, muscle, and bone mineral content. The subject lies on a flat table during the scan.
Baseline, 6, and 12 months
* Record of dietary intake: Parents are asked to write down everything the child eats and drinks for 3 days. Using this record, a dietitian calculates the daily caloric intake.
* Total energy expenditure: This test determines how much energy the child uses. For the test, the child drinks water labeled with harmless isotopes (heavy oxygen and heavy hydrogen). For the next 10 days he collects urine in plastic tubes at home. At the end of the 10 days, the parents bring the urine to the clinic for analysis to determine how fast the labeled water leaves the body. This information is used to calculate how much energy the child expends each day.
Participants' weight is measured at 2 and 4 weeks, and then monthly for the remainder of the 18-month study.
Conditions
- Short Stature
- Constitutional Delay of Growth and Development
- Dwarfism, Pituitary
Interventions
- DRUG
-
Growth Hormone Therapy
Sponsors & Collaborators
-
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
lead NIH
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 7 Years
- Max Age
- 10 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-01-19
- Completion
- 2007-10-02
Countries
- United States
Study Locations
More Related Trials
-
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin
NCT00488124 ·Status: COMPLETED ·Phase: PHASE2
-
Growth Hormone and Endothelial Function in Children
NCT00373386 ·Status: COMPLETED ·Phase: PHASE4
-
Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children
NCT01237041 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
NCT00840944 ·Status: UNKNOWN ·Phase: PHASE4
-
Long Term Effects of Nutritional Supplementation on Final Height
NCT03323177 ·Status: WITHDRAWN ·Phase: NA
-
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
NCT00102817 ·Status: COMPLETED ·Phase: PHASE3
-
Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature
NCT00396097 ·Status: COMPLETED ·Phase: PHASE3
-
Skeletal Muscle Effects of GH in Boys
NCT04020913 ·Status: COMPLETED
-
Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency
NCT03288103 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluating the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Boys
NCT02389803 ·Status: COMPLETED ·Phase: NA
-
Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature
NCT00001190 ·Status: COMPLETED ·Phase: PHASE2
-
Growth Hormone Therapy in Osteogenesis Imperfecta
NCT00001305 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Growth Hormone (GH) Treatment on Eating Regulation
NCT00562705 ·Status: COMPLETED ·Phase: NA
-
Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children
NCT06103513 ·Status: RECRUITING ·Phase: PHASE3
-
National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients
NCT00097513 ·Status: COMPLETED
-
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
NCT01438801 ·Status: WITHDRAWN ·Phase: PHASE4
-
Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency
NCT01502124 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly
NCT00004332 ·Status: COMPLETED
-
National Cooperative Growth Study in CKD
NCT00616278 ·Status: COMPLETED
-
Drug Use Investigation of Somatropin for GHD-ADULTS.
NCT00601419 ·Status: COMPLETED
-
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study
NCT03709381 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood
NCT00212758 ·Status: COMPLETED ·Phase: PHASE4
-
Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
NCT00458263 ·Status: COMPLETED ·Phase: PHASE4
-
Short Stature Related Distress
NCT01246219 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
NCT01009905 ·Status: COMPLETED